Related Experiment Video

Updated: Jan 2, 2026

Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood
13:14

Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood

Published on: February 6, 2018

10.9K

Targeted selection of HIV-specific antibody mutations by engineering B cell maturation

Kevin O Saunders1,2,3, Kevin Wiehe4, Ming Tian5

  • 1Human Vaccine Institute and Department of Surgery, Duke University School of Medicine, Durham, NC 27710, USA. kevin.saunders@duke.edu barton.haynes@duke.edu alt@enders.tch.harvard.edu.

Science (New York, N.Y.)
|December 7, 2019
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Assessing Somatic Hypermutation in Ramos B Cells after Overexpression or Knockdown of Specific Genes08:12

Assessing Somatic Hypermutation in Ramos B Cells after Overexpression or Knockdown of Specific Genes

Published on: November 1, 2011

20.3K
Stem-cell Based Engineered Immunity Against HIV Infection in the Humanized Mouse Model11:38

Stem-cell Based Engineered Immunity Against HIV Infection in the Humanized Mouse Model

Published on: July 2, 2016

10.9K

Related Concept Videos

Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
17.0K